Hairy Cell Leukemia - Pipeline Review, H2 2015 Is

Released
Hairy Cell Leukemia - Pipeline Review, H2 2015 Summary Global Markets Direct s, Hairy Cell Leukemia Pipeline Review, H2 2015, provides an overview of the Hairy Cell Leukemias therapeutic pipeline. This
report provides comprehensive information on the therapeutic development for Hairy Cell Leukemia,
complete with comparative analysis at various stages, therapeutics assessment by drug target,
mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates,
and featured news and press releases. It also reviews key players involved in the therapeutic
development for Hairy Cell Leukemia and special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy
areas and nearly 3,000 indications. The report is built using data and information sourced from Global
Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations
and featured press releases from company/university sites and industry-specific third party sources, put
together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes
periodic updation following a stringent set of processes that ensures that all the profiles are updated
with the latest set of information. Additionally, processes including live news & deals tracking, browser
based alert-box and clinical trials registries tracking ensure that the most recent developments are
captured on a real time basis. The report enhances decision making capabilities and help to create
effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying
new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the
report may be removed or altered based on the availability and relevance of data for the indicated
disease. Scope - The report provides a snapshot of the global therapeutic landscape of Hairy Cell
Leukemia - The report reviews key pipeline products under drug profile section which includes, product
description, MoA and R&D brief, licensing and collaboration details & other developmental activities The report reviews key players involved in the therapeutics development for Hairy Cell Leukemia and
enlists all their major and minor projects - The report summarizes all the dormant and discontinued
pipeline projects - A review of the Hairy Cell Leukemia products under development by companies and
universities/research institutes based on information derived from company and industry-specific
sources - Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages - A detailed assessment of monotherapy and
combination therapy pipeline projects - Coverage of the Hairy Cell Leukemia pipeline on the basis of
target, MoA, route of administration and molecule type - Latest news and deals relating related to
pipeline products Reasons to buy - Provides strategically significant competitor information, analysis,
and insights to formulate effective R&D development strategies - Identify emerging players with
potentially strong product portfolio and create effective counter-strategies to gain competitive
advantage - Develop strategic initiatives by understanding the focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Hairy Cell
Leukemia - Plan mergers and acquisitions effectively by identifying key players of the most promising
pipeline - Devise corrective measures for pipeline projects by understanding Hairy Cell Leukemia
pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing
strategies by identifying prospective partners with the most attractive projects to enhance and expand

business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and
understanding the factors that drove them from pipeline.
with TOC @ http://www.idatainsights.com/reports-landing-page.php?id=173393/hairy-cellleukemia-pipeline-review-h2-2015

Browse

To Get Sample Copy of Report visit @ http://www.idatainsights.com/reports-landingpage.php?id=173393/hairy-cell-leukemia-pipeline-review-h2-2015

Table of Contents

Introduction 6
Global Markets Direct Report Coverage 6
Hairy Cell Leukemia Overview 7
Therapeutics Development 8
Pipeline Products for Hairy Cell Leukemia - Overview 8
Hairy Cell Leukemia - Therapeutics under Development by Companies 9
Hairy Cell Leukemia - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Unknown Stage Products 13
Hairy Cell Leukemia - Products under Development by Companies 14
Hairy Cell Leukemia - Companies Involved in Therapeutics Development 15
AbbVie Inc. 15
Astellas Pharma Inc. 16
AstraZeneca Plc 17
Biogenomics Limited 18
F. Hoffmann-La Roche Ltd. 19
Inbiopro Solutions Pvt. Ltd. 20
Incyte Corporation 21
2

MedImmune, LLC 22
Novartis AG 23
Hairy Cell Leukemia - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Combination Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
(dabrafenib mesylate + trametinib dimethyl sulfoxide) - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
(INCB-039110 + INCB-040093) - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
AGS-67E - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
AZD-6738 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
IBPB-006IA - Drug Profile 40
3

Product Description 40
Mechanism of Action 40
R&D Progress 40
ibrutinib - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
INCB-39110 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
INCB-40093 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
INCB-50465 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
interferon alfa-2a - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
interferon alfa-2b - Drug Profile 53
Product Description 53
Mechanism of Action 53

R&D Progress 53
interferon alfa-2b - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
moxetumomab pasudotox - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
vemurafenib - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Hairy Cell Leukemia - Recent Pipeline Updates 61
Hairy Cell Leukemia - Dormant Projects 88
Hairy Cell Leukemia - Discontinued Products 89
Hairy Cell Leukemia - Product Development Milestones 90
Featured News & Press Releases 90
May 16, 2013: AstraZeneca's MedImmune Enrolls First Patient In Phase III Leukemia Trial Of
Moxetumomab Pasudotox 90
Appendix 91
Methodology 91
Coverage 91
Secondary Research 91
Primary Research 91
Expert Panel Validation 91
Contact Us 91

Disclaimer 92

Read More
http://www.idatainsights.com/reports-landing-page.php?id=173393/hairy-cellleukemia-pipeline-review-h2-2015
About Us:
iData Insights which operates under Precision Research and Consulting Private Limited is a leading
market research information aggregator and marketing research consulting firm. We conduct both
primary and secondary research. Our work does not end with research it is also involved in distributing
reports for different companies . We provide actionable recommendations and provide our expertise for
business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and
discovery, and then be their guide in the implementation of changes that will make a difference to their
bottom line.
ContactUs:
iData Insights
Tel: 1-866-237-2965
Web: http://www.idatainsights.com
Email: info@idatainsights.com
About iData Insights
We work around the clock until our clients are completely satisfied with their promised results. It is our
mission to provide timely services coupled with acute client care to create a long-lasting relationship
with you. We deliver on our promise to provide results that are essential to the success of your
company. We believe that by doing so, we will earn the trust of our clients for future projects